3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
334
Carcinoma, Non-Small-Cell Lung
262
Ovarian Neoplasms
177
Lung Neoplasms
129
Neoplasms
92
Fallopian Tube Neoplasms
77
Carcinoma, Ovarian Epithelial
63
Neoplasm Metastasis
59
Esophageal Neoplasms
58
Stomach Neoplasms
49
Head and Neck Neoplasms
45
Squamous Cell Carcinoma of Head and Neck
44
Triple Negative Breast Neoplasms
40
Endometrial Neoplasms
37
Adenocarcinoma of Lung
32
Urinary Bladder Neoplasms
28
Esophageal Squamous Cell Carcinoma
26
Unspecified Adult Solid Tumor, Protocol Specific
24
Uterine Cervical Neoplasms
23
Carcinoma
23
Melanoma
22
Breast Neoplasms, Male
22
Small Cell Lung Carcinoma
20
Prostatic Neoplasms
20
Parkinson Disease 4, Autosomal Dominant Lewy Body
20
Adenocarcinoma Of Esophagus
20
Recurrence
19
Brenner Tumor
18
Adenocarcinoma, Bronchiolo-Alveolar
18
Peritoneal Neoplasms
16
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Advanced Unresectable or Metastatic Solid Malignancy
×
Paclitaxel
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts